Mankind Pharma Q4 Results
- BSE: 543904
- NSE: MANKIND
- ISIN: INE634S01028
- Sector: Biotechnology & Drugs
BSE
2,072.00
8.10 (0.39%)
8.10 (0.39%)Volume7.35 K
Updated: Wed 18 Feb, 2026 | 15:29:52
NSE
2,074.6011.70 (0.57%)
11.70 (0.57%)Volume2.11 L
Updated: Wed 18 Feb, 2026 | 15:29:55
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Quarter ended Mar 25
Note: Comparison is on QoQ basis
Quarterly - Mankind Pharma Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 2,566.74 | 2,976.96 | -0.99% | 1,881.91 | 36.39% |
| Depreciation/ Amortization | 215.56 | 222.60 | 12.10% | 84.85 | 154.04% |
| Operating Income | 440.77 | 590.24 | -30.86% | 484.86 | -9.09% |
| Net Income | 420.77 | 408.75 | 10.66% | 471.24 | -10.71% |
| Other Operating Expenses Total | 782.33 | 846.07 | 3.58% | 503.61 | 55.34% |
| Net Income Before Taxes | 502.06 | 509.00 | 0.95% | 570.16 | -11.94% |
| Total Revenue | 3,007.51 | 3,567.20 | -6.89% | 2,366.76 | 27.07% |
| Selling/ General/ Admin Expenses Total | 702.45 | 823.71 | -1.02% | 567.38 | 23.81% |
| Diluted Normalized EPS | 10.08 | 11.99 | 6.73% | 11.72 | -14.03% |